– Preclinical data provide proof of concept for M002 to restore cellular uptake and lysosomal delivery and attenuate phenotype in mouse models of mucolipidosis type II – – M002 leverages the Company’s proprietary S1S3 bicistronic platform technology in an AAV9 gene therapy to restore mannose 6-phosphate recognition marker on lysosomal enzymes – ST. LOUIS, Mo., …
Continue reading
